Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Eli Lilly (LLY) stock in focus as the company beats Biogen (BIIB) to win regulatory nod in Australia for first ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

(Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), GE Aerospace ...